[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"saptsingle-antiplatelet-therapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:saptsingle-antiplatelet-therapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100616006","efficacy-and-safety-of-intravenous-thrombolysis-in-branch-atheromatous-disease-100616006",false,"NCT07299994","Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease","Efficacy and Safety of Intravenous Thrombolysis in Branch Atheromatous Disease - a Retrospective Data Analysis","Inclusion Criteria:\n\n* aged over 18 years, with acute ischemic stroke and symptom onset no more than 24 hours before admission, who were treated in one of the stroke units of the participating institutions.\n* All enrolled patients must have undergone a cerebral MRI for inclusion:\n\n  1. DWI lesion: single isolated deep subcortical stroke AND\n  2. The affected vessel involves the LSA, PPA, or ACHA, and the infarct lesion on DWI conforms to one of the following characteristics (A, B, OR C):\n\nA. LSA: \"Comma-like\" infarct lesions with \"fan-shaped\" extension from bottom to top in the coronary position OR ≥ 3 layers (layer thickness 5 mm) on axial DWI.\n\nB. PPA: Infarct lesion extending from the deep pons to the ventral pons on axial DWI.\n\nC. ACHA: Infarct within the anterior choroidal artery territory.\n\nExclusion Criteria:\n\n* Typical recent small subcortical infarction (RSSI) (oval, \\\u003C20mm in all axes)\n* ≥ 50% stenosis on the parent artery (i.e., BA, MCA, or ICA)\n* Stroke due to other clearly identified causes or possible cardioembolic etiology.","ALL","18 Years",{"count":19,"type":20},462,"ESTIMATED","OBSERVATIONAL","Rationale and Relevance:\n\nBranch Atheromatous Disease (BAD) describes an atherosclerotic occlusion of one of the deep penetrating cerebral arteries, including the lenticulostriate artery (LSA), paramedian pontine artery (PPA), and anterior choroidal artery (ACHA). BAD is frequently associated with early neurological deterioration (END), particularly progressive motor deficits that contribute to increased disability. Despite its clinical relevance, BAD remains underrepresented in major radiomorphological classification systems such as TOAST, which has led to limited evidence and unclear treatment strategies. Previous studies suggest that the efficacy of intravenous thrombolysis (IVT) may be reduced in BAD compared to other stroke etiologies.\n\nObjectives:\n\nThe primary objective of this study is to evaluate the efficacy and safety of IVT compared with single antiplatelet therapy (SAPT) and dual antiplatelet therapy (DAPT) in patients with BAD-related stroke. A secondary objective is to examine the impact of acute-phase blood pressure fluctuations on END and functional neurological outcomes.\n\nDesign and Methods:\n\nThis international multicenter study will be conducted retrospectively according to the STROBE guidelines. Eligible patients include those with BAD-related stroke treated at one of the participating centers between 2010 and 2025. Inclusion criteria comprise characteristic diffusion-weighted MRI patterns in predefined vascular territories (LSA, PPA, ACHA) and a symptom onset ≤24 hours before admission. Patients with typical lacunar infarcts or with other identified stroke etiologies will be excluded.\n\nEndpoints:\n\nPrimary endpoints include functional outcome at three months, defined as a favorable outcome with a modified Rankin Scale score of 0-1; occurrence of END, defined as a ≥4-point worsening on the NIHSS within 24-48 hours; and symptomatic intracerebral hemorrhage. Collected data include clinical, imaging, and therapeutic variables, as well as blood pressure trajectories and pre-stroke treatments (as detailed in the study protocol).\n\nStatistical Analysis:\n\nAnalyses will be performed using SPSS and R. Descriptive statistics, univariate analyses, and multivariable models (IPTW and Poisson regression) will be applied. Results will be reported as adjusted relative risks with 95% confidence intervals.\n\nSignificance:\n\nThis study will provide the first comprehensive evaluation of IVT versus SAPT\u002FDAPT in BAD-related stroke, and will investigate the clinical impact of blood pressure changes in this specific stroke subtype. The findings aim to support evidence-based treatment recommendations for a currently underrecognized and poorly understood stroke etiology.",[24,25,26,27,28],"Stroke","Thrombolysis","DAPT(Dual Antiplatelet Therapy)","SAPT(Single Antiplatelet Therapy)","Acute Ischemic Stroke",[30,31,25,32,33],"Acute ischemic Stroke","Branch Atheromatous Disease","DAPT","SAPT","NOT_YET_RECRUITING","2025-12-10",{"date":37,"type":38},"2025-12-23","ACTUAL",{"date":40,"type":20},"2026-01-01",{"date":42,"type":20},"2026-04-30",{"name":44,"class":45},"Sigmund Freud PrivatUniversitat","OTHER",7,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":16,"minAge":53,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100516645","phase-4-non-antithrombotic-therapy-after-transcatheter-aortic-valve-implantation-trial-100516645","NCT06007222","Non-antithrombotic Therapy After Transcatheter Aortic Valve Implantation Trial","Inclusion Criteria:\n\n1. Patients who underwent transfemoral TAVI for aortic stenosis\n2. Patients aged 20 years or older at the time of informed consent\n3. Patients who have a thorough understanding of the subject of the study and who have agreed in writing to participate in the study\n\nExclusion Criteria:\n\n1. Those with perioperative complications at the time of TAVI (conversion to open heart surgery, coronary artery occlusion, annulus rupture, cardiac tamponade, vascular dissection, cerebral infarction\u002Fcerebral hemorrhage, new atrial fibrillation, new atrioventricular block)\n2. Individuals requiring antiplatelet agents for reasons other than TAVI (history of myocardial infraction, history of PCI（Percutaneous Coronary Intervention）, history of EVT（EndoVascular Treatment）, history of cerebral infraction and transient ischaemic stroke, with significant coronary artery narrowing, with high-grade carotid artery narrowing, and others judged as requiring antiplatelet therapy by the chief researcher or a sub-investigator)\n3. Patients requiring oral anticoagulants (patients with atrial fibrillation, history of pulmonary embolism or deep venous thrombosis, and other patients who are deemed to require anticoagulation therapy by the investigator or coinvestigator)\n4. Patients with eGFR（estimated Glomerular Filtration Rate） \\\u003C30 and patients on hemodialysis\u002Fperitoneal dialysis.\n5. Patients with a history of valve replacement in the heart valves.\n6. Patients who are pregnant, have childbearing potential, wish to become pregnant, or are breastfeeding.\n7. Patients who have a concomitant medical illness associated with expected survival less than one year.\n8. Patients who have the contraindications for aspirin.\n9. Patients with a diagnosis of severe allergy to aspirin or a history of hypersensitivity.\n10. Patients requiring a legally acceptable representative, patients unable to obtain written informed consent, or patients unable to understand the outline or purpose of the study.\n11. Other patients for whom the principal investigator or the coinvestigator judges the participation in the study inappropriate.","20 Years",{"count":55,"type":20},400,"INTERVENTIONAL",[58],"PHASE4","Aspirin group: Aspirin 100mg will be started within 24 hours after randomization, and continued aspirin 100mg\u002Fday the end of the study period.\n\nNon-antithrombotic group: No antithrombotic agents will be administered after randomization until the end of the study period.",[61,62,63,26,27],"Aortic Stenosis","TAVI(Transcatheter Aortic Valve Implantation)","Aspirin","RECRUITING","2024-09-20",{"date":67,"type":38},"2024-09-23",{"date":69,"type":38},"2023-04-06",{"date":71,"type":20},"2027-12-31",{"name":73,"class":45},"OCEAN-SHD Study Group",1]